Reference summary — not medical advice or a personal risk estimate.
Hydrochlorothiazide (blood-pressure medication)
Common diuretic for hypertension. IARC 2020 review classified it as photosensitiser linked to skin cancer.
Also known as: HCTZ, hydrochlorothiazide
What this does NOT mean
Finding a factor documented in this product category does not establish that ordinary use of hydrochlorothiazide (blood-pressure medication) causes cancer. It means research — through regulatory testing, recall records, or IARC review — has found that chemical present in this category. Whether it matters for you depends on formulation, dose, frequency, and route of exposure.
What has been documented
- HydrochlorothiazideIARC Group 1IARC Group 1Exposure from · high confidence
IARC classified hydrochlorothiazide as Group 1 in 2024 (Monographs Volume 137), for squamous cell carcinoma of the skin and lip cancer.
Evidence source: IARC
How to read this page
A factor appearing on this page means it has been documented in this product category — through EPA / FDA testing, IARC monographs, or regulatory recall records. Whether it presents a meaningful personal risk depends on the specific formulation, dose, and how you're exposed. Click any factor to read what science actually says about it, and where.